Brief: Enveric Biosciences Reports Positive Preclinical Results For Lead Drug Candidate EB-003
28/05/2025 15:47
May 28 (Reuters) - Enveric Biosciences Inc ENVB.O: ENVERIC BIOSCIENCES REPORTS POSITIVE PRECLINICAL RESULTS FOR LEAD DRUG CANDIDATE EB-003 ENVERIC BIOSCIENCES INC - SUPPORT FOR SAFE EXTENDED DAILY ORAL ADMINISTRATION ENVERIC BIOSCIENCES INC - SIGNIFICANT IMPROVEMENTS IN SEVERE CHRONIC DEPRESSION MODEL Source text: ID:nBw7xbqwva Further company coverage: ENVB.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Enveric Biosciences
See all newsBrief: Enveric Biosciences Announces Positive Results From IND-Enabling ADMET Studies
Enveric Biosciences Q2 net loss widens
AtaiBeckley surges after report Lilly poised to buy psychedelic drug developer
Brief: Enveric Biosciences Initiates Investigational New Drug (IND)-Enabling Genotoxicity Studies Of Lead Neuroplastogen Candidate EB-003
Brief: Enveric Biosciences Reports Positive Preclinical Results From Phototoxicity Analysis For Lead Neuroplastogen Candidate Eb-003